KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments: 2009-2025

Historic Short-term Investments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $1.2 billion.

  • Alnylam Pharmaceuticals' Short-term Investments fell 26.17% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $1.7 billion for FY2024, which is 6.46% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Short-term Investments stood at $1.2 billion for Q3 2025, which was down 29.22% from $1.7 billion recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Short-term Investments high stood at $1.7 billion for Q2 2025, and its period low was $1.1 billion during Q2 2021.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Short-term Investments value was $1.6 billion (recorded in 2023), while the average stood at $1.5 billion.
  • Its Short-term Investments has fluctuated over the past 5 years, first spiked by 52.21% in 2021, then declined by 26.17% in 2025.
  • Alnylam Pharmaceuticals' Short-term Investments (Quarterly) stood at $1.5 billion in 2021, then declined by 16.19% to $1.3 billion in 2022, then climbed by 24.47% to $1.6 billion in 2023, then rose by 6.46% to $1.7 billion in 2024, then fell by 26.17% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.6 billion during Q1 2025.